What Is CJC-1295 No Dac?

Visao Geral da Pesquisa

CJC-1295 (no DAC), frequently referred to no(a) scientific literature as Modified GRF (1-29) or Mod GRF 1-29, e um(a) sintetico(a) peptide analog of endogenous hormonio do crescimento-releasing hormone (GHRH). It is derivado(a) de the primeiro(a) 29 aminoacidos do(a) native 44-aminoacido GHRH molecule produziu no(a) hypothalamus, representing the biologically ativo(a) fragment responsavel por stimulating hormonio do crescimento (GH) release do(a) anterior pituitary gland.[1][2] O peptideo foi originalmente desenvolvido(a) by ConjuChem Biotechnologies Inc. (Montreal, Canada) as part do(a) CJC-1295 drug development program, onde the tetrasubstituted core peptide served como o(a) precursor para o(a) long-acting DAC-conjugated variant.[4]

The term "tetrasubstituted" refers to four strategic aminoacido substitutions no(a) native GHRH(1-29) sequence: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27.[2][3] Each substitution serves a specific purpose: position 2 (D-Ala) previne DPP-4 enzymatic cleavage, position 8 (Gln) reduz asparagine rearrangement or amide hidrolise to aspartic acid, position 15 (Ala) aprimora bioactivity, and position 27 (Leu) previne methionine oxidation. These modifications coletivamente extend the meia-vida do(a) mere minutes characteristic of native GHRH to aproximadamente 30 minutes for CJC-1295 (no DAC), dramatically improving biodisponibilidade enquanto preserving ligacao ao receptor characteristics.[1][5]

The "no DAC" designation is criticamente importante para researchers to understand. CJC-1295 with DAC (Drug Affinity Complex) contem an N-epsilon-3-maleimidopropionyl-lysine linker que covalently liga-se a serum albumin, extending the meia-vida to 6–8 days and creating continuous, non-physiological GH estimulacao.[4][8] In contrast, CJC-1295 (no DAC) lacks this conjugation entirely, producing pulsatile GH release que mimics the body's natural circadian rhythm. This pulsatile pattern is therapeutically preferred porque it avoids receptor dessensibilizacao (downregulacao) of GHRH receptors and minimizes efeitos colaterais associado(a) com cronico(a) GH elevation.[5][6] The FDA, in its December 2024 Pharmacy Compounding Advisory Committee briefing, explicitly observado(a) que muitos(as) studies cited sob o(a) name "CJC-1295" actually utilized the DAC variant, and que no published human ensaios clinicos or preclinical efficacy studies exist specifically for CJC-1295 sem DAC.[9]

Research into CJC-1295 (no DAC) focuses on conditions driven by hormonio do crescimento deficiency (GHD) or age-related decline do(a) GH/IGF-1 axis. Key investigacional areas include composicao corporal and muscle hypertrophy (via GH-mediated protein synthesis and IGF-1 estimulacao), lipid metabolismo (GH-facilitou lipolysis and reduziu visceral tecido adiposo), reparo tecidual and injury recovery (sintese de colageno estimulacao via o(a) GH/IGF-1 axis), sleep physiology (GHRH analogs and slow-wave sleep enhancement), and anti-envelhecimento cellular function (restoring youthful GH pulsatility).[6][7][12] It is frequently studied em combinacao com Ipamorelin, a selective GH secretagogue que acts on a complementary receptor (the ghrelin/GHS receptor), for a synergistic effect on GH release.[12]

Forensic and analytical chemistry studies by Henninge et al. (2010) and Hartvig et al. (2014) have confirmou que products marketed as "CJC-1295" no(a) grey market frequently contain the no-DAC variant (Modified GRF 1-29) rather do que the genuine CJC-1295 with DAC, underscoring the importance of precise nomenclature and rigorous analytical verification using RP-HPLC and LC-MS/MS.[1][3][13]